Axsome Therapeutics
AXSM
11 hedge funds and large institutions have $47.7M invested in Axsome Therapeutics in 2015 Q4 according to their latest regulatory filings, with 11 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$25.3M |
| 2 |
JP Morgan Chase
New York
|
+$13.7M |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$3M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.94M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
+$1.03M |
Top Sellers
AXSM Hedge Fund Activity: Q4 2015 in Review
11 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q4 2015, worth a combined $47.7M.
Buyers outnumbered sellers: 11 funds opened new AXSM positions and 0 closed out — a net gain of 11 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $25.3M.
- 11 institutional investors held Axsome Therapeutics (AXSM) as of Q4 2015, up from 0 in Q3 2015.
- Funds reported $47.7M of Axsome Therapeutics stock for Q4 2015.
- 11 funds opened new Axsome Therapeutics positions in Q4 2015 and 0 closed out, a net change of +11 holders.
- The largest Axsome Therapeutics buyer in Q4 2015 was Fidelity Investments, an estimated $25.3M added.
Based on aggregated 13F filings for Q4 2015.